Theodorescu, MD, PhD, director of the University of Colorado Cancer
Center, has been elected to the Institute of Medicine (IOM). Election to
the IOM is one of the highest honors in health and medicine and recognizes individuals
for their outstanding professional achievement and commitment to service.
“My election to the Institute of Medicine is humbling,” says Theodorescu.
“To be recognized by IOM is a great honor and motivates me even more to find
ways to treat this horrible disease.”
New IOM members are elected by current active members through a selective
process that recognizes individuals who have made major contributions to the
advancement of the medical sciences, health care, and public health.
Most recently, Theodorescu was senior author on a paper in the journal NATURE
that identified Ral protein activation as a new target in the growth and spread
of cancer and developed drug candidates to block its activation. This new class
of drugs could have applications in lung, colon and pancreatic cancers.
School of Medicine, is also a developer of the COXEN (CO eXpression
ExtrapolatioN) bioinformatic principle of personalized therapy assignment in
cancer. It is currently being tested in a national clinical trial through SWOG,
a cancer research cooperative group, funded through the National Institutes of
Health (www.clinicaltrials.gov ,
Richard D. Krugman, MD, dean of the CU School of Medicine and the
University’s vice chancellor of health affairs, who was elected to the IOM in
2005, said Theodorescu’s election recognizes him for leadership and the high
quality of his research.
“Dan is making a difference every day,” Krugman said. “Survival rates for
those who are diagnosed with advanced cancer are significantly higher at CU
Cancer Center compared with national averages and that is because of the
excellent care and research provided by Dan and his team.”